Long term result of intravitreal bevacizumab in a patient newly transformed to proliferative macular telangiectasia type 2
MEAJO-Middle East African Journal of Ophthalmology. 2013; 20 (4): 360-362
em Inglês
| IMEMR
| ID: emr-148528
ABSTRACT
The clinical and imaging findings and therapeutic outcomes of intravitreal bevacizumab injection in a patient with macular telangiectasia type 2 are described. The patient first presented with the non-proliferative stage of the disease for 4 months, then the disease transformed to the proliferative stage. In the proliferative period, the patient was treated with intravitreal bevacizumab injections as-clinically warranted. Over a follow up period lasting 26 months, the patient received 6 intravitreal bevacizumab injections, the visual acuity improved from 20/100 to 20/40, the central retinal thickness decreased from 318 microns to 198 microns. This case implies that the patients with non-proliferative macular telangiectasia type 2 should be followed carefully for proliferative transformation, and intravitreal bevacizumab treatment seems to be effective for proliferative macular telangiectasia type 2
Buscar no Google
Índice:
IMEMR (Mediterrâneo Oriental)
Assunto principal:
Doenças Retinianas
/
Telangiectasia
/
Injeções Intravítreas
/
Anticorpos Monoclonais Humanizados
Tipo de estudo:
Relato de Casos
Limite:
Feminino
/
Humanos
Idioma:
Inglês
Revista:
Middle East Afr. J. Ophthalmol.
Ano de publicação:
2013
Similares
MEDLINE
...
LILACS
LIS